Oral Semaglutide Delivery May Advance in London

People who inject GLP-1 medicines may one day have an oral option, though the technology has only been studied in preclinical work so far.

Updated on Nov. 3, 2026 in Diabetes

Oral Semaglutide Delivery May Advance in London

BioLife Products Limited will present its oral peptide delivery technology at the LSX Investival Showcase during London Life Sciences Week on November 16, 2026, at Old Billingsgate in London. The company's dissolvable effervescent tablet is designed to help peptide medicines survive gastrointestinal transit, and the technology remains in development and is not approved to treat any disease.

Why it matters

Peptide medicines such as GLP-1 receptor agonists are typically injected because the stomach and gut tend to break them down before they reach the bloodstream. An oral option that could carry these drugs systemically would matter for people managing diabetes and obesity who prefer or need to avoid injections, though the approach is still at a preclinical stage.

The findings come from preclinical studies showing measurable systemic semaglutide exposure following oral administration, which the company says builds on earlier human clinical research involving oral insulin formulations. Preclinical results do not establish safety or effectiveness in people, and no human trial results for the semaglutide formulation were reported.

The players

BioLife Products Limited

A company developing oral delivery technologies for peptide medicines, including a dissolvable effervescent tablet platform.

Dr. Farid Bennis

Founder and inventor of the BioLife technology, who has spent two decades researching oral peptide delivery.

The details

The technology uses a dissolvable effervescent tablet that forms a buffered solution, designed to protect peptides as they pass through the gastrointestinal tract. The buffered solution is intended to support systemic delivery, meaning the drug would reach the bloodstream and circulate through the body. The company's U.S. patent includes claims covering multiple GLP-1 receptor agonists, including semaglutide.

Timeline

  1. November 16, 2026, 3:15 to 3:30 p.m. GMT: BioLife presents at the LSX Investival Showcase at Old Billingsgate, London.

  2. 2042: Extent of protection under the U.S. patent claims.

Health Landscape

Injectable GLP-1 receptor agonists have become a central part of diabetes and obesity treatment, and oral formulations of peptide drugs have long been a research goal because injections are a barrier for many patients. Earlier human research on oral insulin provides the closest precedent, though this new work remains preclinical.

If you manage diabetes or take a GLP-1 medicine, an oral option could eventually reduce the need for injections, but this technology is years from any clinical use. Anyone considering a change in how they take a medication should discuss it with their doctor rather than waiting on preclinical results.

The takeaway

Oral delivery of peptide drugs is a long-running research goal, and this preclinical work is an early step rather than a new treatment. Anyone with questions about current injectable or oral diabetes medications should raise them with their healthcare provider.

What happens next

BioLife will present its oral peptide delivery technology at the LSX Investival Showcase on November 16, 2026, from 3:15 to 3:30 p.m. GMT at Old Billingsgate, London.

Further reading

For broader background on how these drugs are used, see our Diabetes coverage.